HealthEquity Dirección

Dirección controles de criterios 3/4

El CEO de HealthEquity's es Jon Kessler , nombrado en Feb 2014, tiene una permanencia de 10.17 años. compensación anual total es $13.40M, compuesta por 5.2% salario y 94.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.45% de las acciones de la empresa, por valor de €28.89M. La antigüedad media del equipo directivo y de la junta directiva es de 2.7 años y 7.6 años, respectivamente.

Información clave

Jon Kessler

Chief Executive Officer (CEO)

US$13.4m

Compensación total

Porcentaje del salario del CEO	5.2%
Permanencia del CEO	10.3yrs
Participación del CEO	0.5%
Permanencia media de la dirección	2.8yrs
Promedio de permanencia en la Junta Directiva	7.7yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jon Kessler en comparación con los beneficios de HealthEquity?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jan 31 2024	n/a	n/a	US$56m
Oct 31 2023	n/a	n/a	US$29m
Jul 31 2023	n/a	n/a	US$13m
Apr 30 2023	n/a	n/a	-US$8m
Jan 31 2023	US$13m	US$700k	-US$26m
Oct 31 2022	n/a	n/a	-US$59m
Jul 31 2022	n/a	n/a	-US$62m
Apr 30 2022	n/a	n/a	-US$55m
Jan 31 2022	US$10m	US$700k	-US$44m
Oct 31 2021	n/a	n/a	-US$6m
Jul 31 2021	n/a	n/a	US$723k
Apr 30 2021	n/a	n/a	US$4m
Jan 31 2021	US$9m	US$667k	US$9m
Oct 31 2020	n/a	n/a	US$3m
Jul 31 2020	n/a	n/a	-US$20m
Apr 30 2020	n/a	n/a	-US$332k
Jan 31 2020	US$5m	US$500k	US$40m
Oct 31 2019	n/a	n/a	US$53m
Jul 31 2019	n/a	n/a	US$90m
Apr 30 2019	n/a	n/a	US$93m
Jan 31 2019	US$5m	US$483k	US$74m
Oct 31 2018	n/a	n/a	US$67m
Jul 31 2018	n/a	n/a	US$61m
Apr 30 2018	n/a	n/a	US$56m
Jan 31 2018	US$4m	US$400k	US$47m

Compensación vs. Mercado: La compensación total de Jon($USD13.40M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD3.35M).

Compensación vs. Ingresos: La compensación de Jon ha sido consistente con los resultados de la empresa en el último año.

CEO

Jon Kessler (55 yo)

10.3yrs

Permanencia

US$13,400,167

Compensación

Mr. Jon Kessler is a Member of the Board of Managers at HealthEquity Advisors, LLC. He has been the Chief Executive Officer and President of HealthEquity, Inc. since February 2014. Mr. Kessler founded Wage...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jon Kessler	President	10.3yrs	US$13.40m	0.45% $ 28.5m
Stephen Neeleman	Founder & Vice Chairman	21.5yrs	US$2.79m	0.96% $ 60.0m
Elimelech Rosner	Executive VP & CTO	2.2yrs	US$12.51m	0.011% $ 688.8k
James Lucania	CFO & Executive VP	less than a year	sin datos	sin datos
Angelique Hill	Executive Vice President of Operations	6.1yrs	sin datos	sin datos
Richard Putnam	Vice President of Investor Relations	no data	sin datos	sin datos
Delano Ladd	Executive VP	7.7yrs	US$1.53m	0.043% $ 2.7m
Steve Lindsay	Executive Vice President of Sales & Relationship Management	2.8yrs	sin datos	sin datos
Brad Bennion	Senior Vice President of Corporate Development	7.1yrs	sin datos	sin datos
Tia Padia	Executive VP & Chief Marketing Officer	2.3yrs	sin datos	sin datos
Cheryl King	Executive VP & Chief People Officer	1.1yrs	sin datos	sin datos
Kamesh Tumsi	Senior VP & Head of Product	1.5yrs	sin datos	sin datos

2.8yrs

Permanencia media

54.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 2HE se considera experimentado (2.7 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jon Kessler	President	15.2yrs	US$13.40m	0.45% $ 28.5m
Stephen Neeleman	Founder & Vice Chairman	21.5yrs	US$2.79m	0.96% $ 60.0m
Adrian Dillon	Independent Director	7.7yrs	US$375.50k	0.059% $ 3.7m
Robert Selander	Independent Non-Executive Chairman	8.7yrs	US$440.50k	0.049% $ 3.1m
Paul Black	Independent Director	1.7yrs	US$191.81k	0.00071% $ 44.6k
Evelyn Dilsaver	Independent Director	9.8yrs	US$363.00k	0.034% $ 2.1m
Frank Corvino	Independent Director	9.8yrs	US$350.50k	0.0048% $ 301.0k
Stuart Parker	Independent Director	3.4yrs	US$343.00k	0.037% $ 2.4m
Gayle Wellborn	Independent Director	6.8yrs	US$363.00k	0.014% $ 876.7k
Debra McCowan	Independent Director	6.1yrs	US$353.00k	0.0082% $ 516.0k
Rajesh Natarajan	Independent Director	2yrs	US$278.11k	0.0057% $ 361.4k

7.7yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de 2HE se considera experimentada (7.6 años de antigüedad promedio).

HealthEquity Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

HealthEquity, Inc., Annual General Meeting, Jun 27, 2024

HealthEquity, Inc. Announces the Termination of the Employment of Larry Trittschuh, Executive Vice President and Chief Security Officer

Executive VP & CTO recently sold €607k worth of stock

HealthEquity, Inc. Announces Change of CFO

Independent Director recently sold €305k worth of stock

Independent Director recently sold €312k worth of stock

Recent updates

HealthEquity, Inc., Annual General Meeting, Jun 27, 2024

Full year 2024 earnings released: EPS: US$0.65 (vs US$0.31 loss in FY 2023)

HealthEquity, Inc. to Report Q4, 2024 Results on Mar 19, 2024

HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ended January 31, 2024 and Fiscal Year Ending January 31, 2025

Third quarter 2024 earnings released: EPS: US$0.17 (vs US$0.019 loss in 3Q 2023)

HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ending January 31, 2024 and 2025

HealthEquity, Inc. to Report Q3, 2024 Results on Dec 05, 2023

HealthEquity, Inc. (NasdaqGS:HQY) entered into a definitive agreement to acquire BenefitWallet’s Health Savings Account (HSA) portfolio from Conduent Business Services, LLC for $425 million.

Now 21% undervalued

HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ending January 31, 2024

Second quarter 2024 earnings released: EPS: US$0.12 (vs US$0.13 loss in 2Q 2023)

HealthEquity, Inc. to Report Q2, 2024 Results on Sep 05, 2023

HealthEquity, Inc. Announces the Termination of the Employment of Larry Trittschuh, Executive Vice President and Chief Security Officer

Executive VP & CTO recently sold €607k worth of stock

HealthEquity, Inc. Announces Change of CFO

First quarter 2024 earnings released: EPS: US$0.048 (vs US$0.16 loss in 1Q 2023)

HealthEquity, Inc. Provides Earnings Guidance for the Year Ending January 31, 2024

HealthEquity, Inc. to Report Q1, 2024 Results on Jun 05, 2023

Full year 2023 earnings released: US$0.31 loss per share (vs US$0.53 loss in FY 2022)

Now 22% undervalued after recent price drop

Independent Director recently sold €305k worth of stock

HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ending January 31, 2023 and January 31, 2024

Third quarter 2023 earnings released: US$0.019 loss per share (vs US$0.06 loss in 3Q 2022)

HealthEquity, Inc. to Report Q3, 2023 Results on Dec 06, 2022

Independent Director recently sold €312k worth of stock

Independent Director recently sold €1.8m worth of stock

Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.046 loss in 2Q 2022)

HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ending January 31, 2023

Healthequity, Inc. Elects Paul M. Black to Board of Directors and to Audit and Risk Committee and Talent, Compensation and Culture Committee

HealthEquity, Inc. to Report Q2, 2023 Results on Sep 06, 2022

HealthEquity, Inc. Announces Executive Changes

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.032 loss in 1Q 2022)

HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ending January 31, 2023

HealthEquity, Inc. to Report Q1, 2023 Results on Jun 06, 2022

HealthEquity, Inc., Annual General Meeting, Jun 23, 2022

HealthEquity, Inc. Expands Board of Directors

Insufficient new directors

HealthEquity, Inc. to Report Q4, 2022 Results on Mar 22, 2022

HealthEquity, Inc. Provides Revenue Guidance for the Fiscal Year 2023

Independent Director recently bought €949k worth of stock

HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ending January 31, 2022

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Independent Director recently sold €462k worth of stock

HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ending January 31, 2022

Second quarter 2022 earnings released: EPS US$0.56 (vs US$0.002 loss in 2Q 2021)

Executive Vice President of Sales William Otten has left the company

Independent Director recently sold €647k worth of stock

Independent Director recently sold €290k worth of stock

Healthequity, Inc. Revises Earnings Guidance for the Fiscal Year Ending January 31, 2022

HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ending January 31, 2022

First quarter 2022 earnings released: US$0.032 loss per share (vs US$0.026 profit in 1Q 2021)

HealthEquity, Inc. (NasdaqGS:HQY) entered into a Custodial Transfer and Asset Purchase Agreement to acquire Health Savings Account Business of Fifth Third Bancorp from Fifth Third Bank, National Association for $60.8 million.

Full year 2021 earnings released: EPS US$0.12 (vs US$0.59 in FY 2020)

Full year 2021 earnings released: EPS US$0.12 (vs US$0.59 in FY 2020)

HealthEquity, Inc. (NasdaqGS:HQY) acquired Luum from Evan McCordick for $67.2 million.

HealthEquity, Inc. to Report Q4, 2021 Results on Mar 15, 2021

HealthEquity, Inc. has completed a Follow-on Equity Offering in the amount of $401.5 million.

New 90-day high: €64.00

Independent Director recently sold €202k worth of stock

Executive Vice President of Sales recently sold €103k worth of stock

Revenue beats expectations

Third quarter 2021 earnings released: EPS US$0.023

Healthequity, Inc. Appoints Stuart Parker as A Member of the Board

HealthEquity, Inc. to Report Q3, 2021 Results on Dec 07, 2020

New 90-day high: €53.50

New 90-day low: €42.60

First half earnings released

HealthEquity, Inc. to Report Q2, 2021 Results on Sep 08, 2020

HealthEquity, Inc. has completed a Follow-on Equity Offering in the amount of $257.6 million.